Most of such targeted nanoparticulate systems have been developed for the purpose of cancer management, and have benefited from the conjugation of affibodies against human epidermal growth factor receptor 2 (HER-2) to various types of nanoparticles [297,298] and liposomes [299]. The gene discussed is ERBB2; the disease is cancer.